Introduction:
As the pharmaceutical industry continues to evolve, Denmark has emerged as a key player in the biologics and biosimilars market. With a focus on innovation and high-quality products, Danish companies are making significant contributions to the global healthcare sector. In 2026, the top 10 biologics and biosimilars companies in Denmark are at the forefront of research and development, driving growth and shaping the future of the industry.
Top 10 Biologics & Biosimilars Companies in Denmark 2026:
1. Novo Nordisk
Novo Nordisk is a leading global healthcare company, specializing in diabetes care and other chronic diseases. With a market share of over 30% in the biologics and biosimilars sector, Novo Nordisk continues to expand its product portfolio and reach new markets.
2. Genmab
Genmab is a biotechnology company focused on the discovery and development of innovative antibody therapeutics. With a production volume of over 1,000,000 units per year, Genmab is known for its cutting-edge research and commitment to improving patient outcomes.
3. Lundbeck
Lundbeck is a pharmaceutical company dedicated to developing treatments for brain disorders, such as depression and Alzheimer’s disease. With exports to over 50 countries, Lundbeck is a key player in the biologics and biosimilars market, driving growth and innovation.
4. Bavarian Nordic
Bavarian Nordic is a biotechnology company specializing in vaccines for infectious diseases, including smallpox and Ebola. With a trade value of over $500 million, Bavarian Nordic is a major player in the global biologics market, with a strong focus on research and development.
5. Zealand Pharma
Zealand Pharma is a biotechnology company focused on the discovery and development of innovative peptide-based therapeutics. With a market share of over 15%, Zealand Pharma is known for its pipeline of promising drug candidates and commitment to improving patient care.
6. Orphazyme
Orphazyme is a biopharmaceutical company dedicated to developing treatments for rare genetic diseases. With a production volume of over 500,000 units per year, Orphazyme is a key player in the biologics and biosimilars market, driving innovation and improving patient outcomes.
7. Symphogen
Symphogen is a biotechnology company specializing in the discovery and development of antibody therapeutics for cancer and autoimmune diseases. With exports to over 30 countries, Symphogen is a global leader in the biologics sector, with a strong focus on research and development.
8. Ascendis Pharma
Ascendis Pharma is a biopharmaceutical company focused on developing long-acting prodrug therapies for rare diseases. With a trade value of over $300 million, Ascendis Pharma is a key player in the biologics market, driving growth and innovation in the industry.
9. 2cureX
2cureX is a biotechnology company specializing in personalized medicine and drug response prediction. With a market share of over 10%, 2cureX is known for its innovative approach to patient care and commitment to improving treatment outcomes.
10. Orpharm
Orpharm is a pharmaceutical company dedicated to developing treatments for rare and orphan diseases. With a production volume of over 300,000 units per year, Orpharm is a key player in the biologics and biosimilars market, driving growth and innovation in the industry.
Insights:
Looking ahead to the future, the biologics and biosimilars market in Denmark is poised for continued growth and innovation. With an increasing focus on personalized medicine and patient-centric care, Danish companies are at the forefront of research and development, driving new discoveries and improving treatment outcomes. In 2026, the top 10 biologics and biosimilars companies in Denmark will continue to shape the future of the industry, driving growth and innovation on a global scale. With a strong commitment to quality and innovation, Danish companies are well-positioned to lead the way in the evolving healthcare landscape.
Related Analysis: View Previous Industry Report
